You are hereReuters: US Supreme Court won't review drug patent deal

Reuters: US Supreme Court won't review drug patent deal

The Supreme Court let stand a ruling that drug companies can pay rivals to delay production of generic drugs without violating federal antitrust laws.

March 7, 2011- The justices refused to review a U.S. appeals court ruling that upheld the dismissal of a legal challenge to a deal between Bayer AG and Teva Pharmaceutical Industries Ltd's Barr Laboratories. Bayer paid Barr to prevent it from bringing to market a version of the antibiotic drug Cipro.

When the Supreme Court refuses to hear an appeal, as in the Cipro case, it is not a ruling on the merits of the dispute and it does not set a national precedent.

The Cipro deal, involving Bayer's 1997 settlement of patent litigation with Barr, was challenged by a number of pharmacies, which appealed to the Supreme Court. More than 30 states and various consumer groups supported the appeal.

The Federal Trade Commission has opposed such deals and has supported legislation pending in Congress to prohibit such settlements, which it says have increased in recent years.

The FTC has also taken companies to court for so-called "reverse payment" deals, where brand name companies pay generic drug firms to stay out of the market.

Richard Feinstein, head of the FTC's antitrust division, said the deals cost American consumers billions of dollars per year in higher drug costs.



Backbone Campaign
Liberty Tree
Progressive Democrats of America
Peoples Email Network
Justice Through Music
Locust Fork Journal
Berkeley Fellowship UU\'s Social Justice Committee
The Smirking Chimp
Progressive Democrats Sonoma County
Center for Media and Democracy
Chelsea Neighbors United
Atlanta Progressive News
Yes Men
No Nukes North